Real-world effects of two inhaled corticosteroid/long-acting β2-agonist combinations in the treatment of asthma

摘要

Objective: There are several inhaled corticosteroid/long-acting β2-agonist (ICS/LABA) combinations currently used to treat asthmatic patients, but the differences in the clinical effects of these ICS/LABAs are currently unknown. We herein evaluated the effects of two currently available ICS/LABA combinations in a real-world setting. Methods: A fluticasone propionate/salmeterol combined Discus inhaler (FP/SM; 250/50μg bid) was switched to a budesonide/formoterol Turbuhaler inhaler (BUD/FM; 160/4.5μg two inhalations bid) and FP/SM (500/50μg bid) was also switched to BUD/FM (160/4.5μg four inhalations bid) in symptomatic asthmatic patients treated with FP/SM over 20 years of age. Results: Sixty patients were enrolled in this study, and the scores of the asthma control test (ACT) and asthma control questionnaire-5 item version (ACQ5) were significantly improved 4 and 8 weeks after the switch to ICS/LABA treatments, and well-controlled asthma (ACQ5 score 0.75) and good control (ACT score 20) was achieved in 54 (90%) and 40 (66.7%) patients, respectively, at 8 weeks. The spirometric analysis revealed significant improvements of the values of the peak expiratory flow (PEF) and forced expiratory volume in one second (FEV1) after switching from FP/SM to BUD/FM, and significantly improved small airway impairments (V 50 and V25) were observed in patients treated with high-dose ICS/LABA. These subjective and objective improvements were also seen in patients aged over 65 years old. Conclusion: These data demonstrated that changing the combined ICS/LABA inhaler from FP/SM to BUD/FM can lead to more effective management of symptomatic patients with asthma, especially in patients treated with high-dose ICS/LABA.